{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,15]],"date-time":"2026-10-15T03:08:14Z","timestamp":1792033694217,"version":"4.4.0"},"reference-count":37,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2017,11,1]],"date-time":"2017-11-01T00:00:00Z","timestamp":1509494400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"funder":[{"DOI":"10.13039\/100000054","name":"National Cancer Institute","doi-asserted-by":"publisher","award":["CA 27469"],"award-info":[{"award-number":["CA 27469"]}],"id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000054","name":"National Cancer Institute","doi-asserted-by":"publisher","award":["CA 37517"],"award-info":[{"award-number":["CA 37517"]}],"id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000054","name":"National Cancer Institute","doi-asserted-by":"publisher","award":["U10 CA180868"],"award-info":[{"award-number":["U10 CA180868"]}],"id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000054","name":"National Cancer Institute","doi-asserted-by":"publisher","award":["U10 CA180822"],"award-info":[{"award-number":["U10 CA180822"]}],"id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.jp","clinicalkey.com","clinicalkey.es","clinicalkey.com.au","clinicalkey.fr","gynecologiconcology-online.net","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Gynecologic Oncology"],"published-print":{"date-parts":[[2017,11]]},"DOI":"10.1016\/j.ygyno.2017.08.001","type":"journal-article","created":{"date-parts":[[2017,8,10]],"date-time":"2017-08-10T09:33:57Z","timestamp":1502357637000},"page":"283-290","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":61,"title":["A phase I trial of intraperitoneal GEN-1, an IL-12 plasmid formulated with PEG-PEI-cholesterol lipopolymer, administered with pegylated liposomal doxorubicin in patients with recurrent or persistent epithelial ovarian, fallopian tube or primary peritoneal cancers: An NRG Oncology\/Gynecologic Oncology Group study"],"prefix":"10.1016","volume":"147","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-0568-6959","authenticated-orcid":false,"given":"Premal H.","family":"Thaker","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"William E.","family":"Brady","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Heather A.","family":"Lankes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kunle","family":"Odunsi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"William H.","family":"Bradley","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kathleen N.","family":"Moore","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carolyn Y.","family":"Muller","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Khursheed","family":"Anwer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Russell J.","family":"Schilder","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ronald D.","family":"Alvarez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paula M.","family":"Fracasso","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ygyno.2017.08.001_bb0005","series-title":"SEER Cancer Statistics Review","author":"Howlader","year":"1975"},{"key":"10.1016\/j.ygyno.2017.08.001_bb0010","doi-asserted-by":"crossref","first-page":"751","DOI":"10.1517\/14712598.2011.566854","article-title":"Evaluating the role of IL-12 based therapies in ovarian cancer: a review of the literature","volume":"11","author":"Whitworth","year":"2011","journal-title":"Expert. Opin. Biol. Ther."},{"key":"10.1016\/j.ygyno.2017.08.001_bb0015","first-page":"111","article-title":"Direct in vitro evidence and in vivo analysis of the anti-angiogenesis effects of interleukin 12","volume":"60","author":"Duda","year":"2000","journal-title":"Cancer Res."},{"key":"10.1016\/j.ygyno.2017.08.001_bb0020","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1186\/1479-5876-5-66","article-title":"Phase II study of intraperitoneal recombinant interleukin-12 (rhIL-12) in patients with peritoneal carcinomatosis (residual disease <1cm) associated with ovarian cancer or primary peritoneal carcinoma","volume":"5","author":"Lenzi","year":"2007","journal-title":"J. Transl. Med."},{"key":"10.1016\/j.ygyno.2017.08.001_bb0025","doi-asserted-by":"crossref","first-page":"288","DOI":"10.1016\/j.jconrel.2005.09.024","article-title":"Synthesis and application of biocompatible non-viral gene delivery system for immunogene therapy of cancer","volume":"109","author":"Fewell","year":"2005","journal-title":"J. Control. Release"},{"key":"10.1016\/j.ygyno.2017.08.001_bb0030","first-page":"3304","article-title":"Use of interleukin-12 gene nanocomplexes as a general treatment against disseminated peritoneal malignancies","volume":"48","author":"Fewell","year":"2007","journal-title":"Proc Am Assoc Cancer Res"},{"key":"10.1016\/j.ygyno.2017.08.001_bb0035","doi-asserted-by":"crossref","first-page":"718","DOI":"10.1002\/jgm.1356","article-title":"Treatment of disseminated ovarian cancer using nonviral interleukin-12 gene therapy delivered intraperitoneally","volume":"11","author":"Fewell","year":"2009","journal-title":"J. Gene Med."},{"key":"10.1016\/j.ygyno.2017.08.001_bb0040","doi-asserted-by":"crossref","first-page":"360","DOI":"10.1038\/gt.2009.159","article-title":"Phase-I clinical trial of IL-12 plasmid\/lipopolymer complexes for the treatment of recurrent ovarian cancer","volume":"17","author":"Anwer","year":"2010","journal-title":"Gene Ther."},{"key":"10.1016\/j.ygyno.2017.08.001_bb0045","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1016\/j.ygyno.2013.07.081","article-title":"Phase I trial of a formulated IL-12 plasmid in combination with carboplatin and docetaxel chemotherapy in the treatment of platinum-sensitive recurrent ovarian cancer","volume":"131","author":"Anwer","year":"2013","journal-title":"Gynecol. Oncol."},{"key":"10.1016\/j.ygyno.2017.08.001_bb0050","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1053\/j.seminoncol.2004.08.004","article-title":"Liposomal anthracycline treatment for ovarian cancer","volume":"31","author":"Markman","year":"2004","journal-title":"Semin. Oncol."},{"key":"10.1016\/j.ygyno.2017.08.001_bb0055","doi-asserted-by":"crossref","first-page":"3093","DOI":"10.1200\/JCO.2000.18.17.3093","article-title":"Phase II study of liposomal doxorubicin in platinum- and paclitaxel-refractory epithelial ovarian cancer","volume":"18","author":"Gordon","year":"2000","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.ygyno.2017.08.001_bb0060","doi-asserted-by":"crossref","first-page":"3841","DOI":"10.1200\/JCO.2011.38.8082","article-title":"Randomized, open-label phase III study comparing patupilone (EPO906) with pegylated liposomal doxorubicin in platinum-refractory or -resistant patients with recurrent epithelial ovarian, primary fallopian tube, or primary peritoneal cancer","volume":"30","author":"Colombo","year":"2012","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.ygyno.2017.08.001_bb0065","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1007\/s10555-011-9273-4","article-title":"Molecular determinants of immunogenic cell death elicited by anticancer chemotherapy","volume":"30","author":"Kepp","year":"2011","journal-title":"Cancer Metastasis Rev."},{"key":"10.1016\/j.ygyno.2017.08.001_bb0070","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1016\/j.ejca.2008.10.026","article-title":"New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1)","volume":"45","author":"Eisenhauer","year":"2009","journal-title":"Eur. J. Cancer"},{"key":"10.1016\/j.ygyno.2017.08.001_bb0075","doi-asserted-by":"crossref","first-page":"708","DOI":"10.1093\/jnci\/djp079","article-title":"Dose escalation methods in phase I cancer clinical trials","volume":"101","author":"Le Tourneau","year":"2009","journal-title":"J. Natl. Cancer Inst."},{"key":"10.1016\/j.ygyno.2017.08.001_bb0080","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1186\/1479-5876-5-32","article-title":"Circulating protein biomarkers of pharmacodynamics activity of sunitinib in patients with metastatic renal carcinoma: modulation of VEGF and VEGF-related proteins","volume":"5","author":"Deprimo","year":"2007","journal-title":"J. Transl. Med."},{"key":"10.1016\/j.ygyno.2017.08.001_bb0085","doi-asserted-by":"crossref","first-page":"57197","DOI":"10.18632\/oncotarget.11084","article-title":"The VEGF rise in blood of bevacizumab patients is not based on tumor escape but a host-blockade of VEGF clearance","volume":"7","author":"Alidzanovic","year":"2016","journal-title":"Oncotarget"},{"key":"10.1016\/j.ygyno.2017.08.001_bb0090","doi-asserted-by":"crossref","first-page":"3749","DOI":"10.1073\/pnas.1014480108","article-title":"Anti-VEGF treatment reduces blood supply and increases tumor cell invasion in glioblastoma","volume":"108","author":"Keunen","year":"2011","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.ygyno.2017.08.001_bb0095","doi-asserted-by":"crossref","first-page":"9886","DOI":"10.1158\/0008-5472.CAN-10-1419","article-title":"Increase of plasma VEGF after intravenous administration of bevacizumab is predicted by a pharmacokinetic model","volume":"70","author":"Stefnani","year":"2010","journal-title":"Cancer Res."},{"key":"10.1016\/j.ygyno.2017.08.001_bb0100","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1016\/j.ygyno.2014.03.571","article-title":"A phase II trial of intraperitoneal EGEN-001, an IL-12 plasmid formulated with PEG-PEI-cholesterol lipopolymer in the treatment of persistent or recurrent epithelial ovarian, fallopian tube or primary peritoneal cancer: a Gynecologic Oncology Group study","volume":"133","author":"Alvarez","year":"2014","journal-title":"Gynecol. Oncol."},{"key":"10.1016\/j.ygyno.2017.08.001_bb0105","doi-asserted-by":"crossref","first-page":"4252","DOI":"10.1158\/1078-0432.CCR-06-2894","article-title":"Doxorubicin directs the accumulation of interleukin-12 induced IFN gamma into tumors for enhancing STAT1 dependent anti-tumor effect","volume":"13","author":"Zhu","year":"2007","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.ygyno.2017.08.001_bb0110","doi-asserted-by":"crossref","first-page":"720","DOI":"10.1002\/(SICI)1097-0215(19980831)77:5<720::AID-IJC10>3.0.CO;2-5","article-title":"Effective chemo-immunomodulatory of L1210 leukemia in vivo using interleukin-12 combined with doxorubicin but not with cyclophosphamide, paclitaxel or cisplatin","volume":"77","author":"Zagozdon","year":"1998","journal-title":"Int. J. Cancer"},{"key":"10.1016\/j.ygyno.2017.08.001_bb0115","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1186\/1479-5876-7-104","article-title":"Increased immunogenicity of surviving tumor cells enables cooperation between liposomal doxorubicin and IL-18","volume":"7","author":"Alagkiozidis","year":"2009","journal-title":"J. Transl. Med."},{"key":"10.1016\/j.ygyno.2017.08.001_bb0120","first-page":"1661","article-title":"Optimal scheduling of interleukin 12 and chemotherapy in the murine MB-49 bladder carcinoma and B16 melanoma","volume":"3","author":"Teicher","year":"1997","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.ygyno.2017.08.001_bb0125","doi-asserted-by":"crossref","first-page":"4461","DOI":"10.1158\/0008-5472.CAN-05-3554","article-title":"Stat1 deficiency in the host enhances interleukin-12-mediated tumor regression","volume":"66","author":"Torrerro","year":"2006","journal-title":"Cancer Res."},{"key":"10.1016\/j.ygyno.2017.08.001_bb0130","doi-asserted-by":"crossref","first-page":"463","DOI":"10.1007\/s00262-003-0391-x","article-title":"Doxorubicin induces specific immune functions and cytokine expression in the peritoneal cells","volume":"52","author":"Ujhazy","year":"2003","journal-title":"Cancer Immunol. Immunother."},{"key":"10.1016\/j.ygyno.2017.08.001_bb0135","first-page":"1719","article-title":"Increased primary cell mediated immunity in culture subsequent to Adriamycin or daunorubicin treatment of spleen donor mice","volume":"37","author":"Orsini","year":"1997","journal-title":"Cancer Res."},{"key":"10.1016\/j.ygyno.2017.08.001_bb0140","first-page":"3572","article-title":"Adriamycin-induced modulation of host defenses in tumor-bearing mice","volume":"52","author":"Maccubbin","year":"1992","journal-title":"Cancer Res."},{"key":"10.1016\/j.ygyno.2017.08.001_bb0145","first-page":"130","article-title":"Alterations in murine host defense functions by Adriamycin or liposome-encapsulated Adriamycin","volume":"48","author":"Mace","year":"1988","journal-title":"Cancer Res."},{"key":"10.1016\/j.ygyno.2017.08.001_bb0150","first-page":"74104","article-title":"Doxorubicin eliminates myeloid-derived suppressor cells and enhances the efficacy of adoptive T-cell transfer in breast cancer","author":"Alizadeh","year":"2014","journal-title":"Cancer Res."},{"key":"10.1016\/j.ygyno.2017.08.001_bb0155","doi-asserted-by":"crossref","first-page":"2811","DOI":"10.1200\/JCO.2006.09.6735","article-title":"Randomized phase III trial of gemcitabine compared with pegylated liposomal doxorubicin in patients with platinum-resistant ovarian cancer","volume":"25","author":"Mutch","year":"2007","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.ygyno.2017.08.001_bb0160","doi-asserted-by":"crossref","first-page":"3312","DOI":"10.1200\/JCO.2001.19.14.3312","article-title":"Recurrent epithelial ovarian carcinoma: a randomized phase III study of pegylated liposomal doxorubicin versus topotecan","volume":"19","author":"Gordon","year":"2001","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.ygyno.2017.08.001_bb0165","first-page":"1678","article-title":"Phase I trial of twice-weekly intravenous IL-12 in patients with metastatic renal cancer or malignant melanoma: ability to maintain IFN-gamma induction is associated with clinical response","volume":"6","author":"Gollob","year":"2000","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.ygyno.2017.08.001_bb0170","doi-asserted-by":"crossref","first-page":"4120","DOI":"10.4049\/jimmunol.165.7.4120","article-title":"Impairment of STAT activation by IL-12 in a patient with atypical mycobacterial and staphylococcal infections","volume":"65","author":"Gollob","year":"2000","journal-title":"J. Immunol."},{"key":"10.1016\/j.ygyno.2017.08.001_bb0175","doi-asserted-by":"crossref","first-page":"e218","DOI":"10.1016\/S1470-2045(12)70582-X","article-title":"Cytokine patterns in patients with cancer: a systematic review","volume":"14","author":"Lippitz","year":"2013","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.ygyno.2017.08.001_bb0180","doi-asserted-by":"crossref","first-page":"176","DOI":"10.3109\/08977194.2012.678843","article-title":"Interleukin-12: clinical usage and molecular markers of cancer susceptibility","volume":"30","author":"Yuzhalin","year":"2012","journal-title":"Growth Factors"},{"key":"10.1016\/j.ygyno.2017.08.001_bb0185","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2016.34.15_suppl.TPS5605","article-title":"Phase I study of the safety and biological activity of intraperitoneal IL-12 plasmid formulated with PEG-PEI-cholesterol lipopolymer administered in combination with standard neoadjuvant chemotherapy in patients with newly diagnosed ovarian cancer","volume":"34","author":"Thaker","year":"2016","journal-title":"J. Clin. Oncol."}],"container-title":["Gynecologic Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0090825817311861?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0090825817311861?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2019,10,2]],"date-time":"2019-10-02T03:10:41Z","timestamp":1569985841000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0090825817311861"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,11]]},"references-count":37,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2017,11]]}},"alternative-id":["S0090825817311861"],"URL":"https:\/\/doi.org\/10.1016\/j.ygyno.2017.08.001","relation":{},"ISSN":["0090-8258"],"issn-type":[{"value":"0090-8258","type":"print"}],"subject":[],"published":{"date-parts":[[2017,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"A phase I trial of intraperitoneal GEN-1, an IL-12 plasmid formulated with PEG-PEI-cholesterol lipopolymer, administered with pegylated liposomal doxorubicin in patients with recurrent or persistent epithelial ovarian, fallopian tube or primary peritoneal cancers: An NRG Oncology\/Gynecologic Oncology Group study","name":"articletitle","label":"Article Title"},{"value":"Gynecologic Oncology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ygyno.2017.08.001","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2017 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}